Author: Ken Dropiewski

ABBOTT ANNOUNCES ROBERT B. FORD TO SUCCEED MILES D. WHITE AS CHIEF EXECUTIVE OFFICER ON MARCH 31, 2020

– Mr. White will remain Executive Chairman of the Board – Mr. Ford has been elected to the Abbott Board ABBOTT PARK, Ill., Nov. 13, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second […]

Proximo Medical Expands Portfolio with PEDRA™ Technology

Novel technology designed to provide real-time perfusion monitoring CASTLE PINES, Colo., Nov. 13, 2019 /PRNewswire/ — Proximo Medical, LLC today announced a partnership with PEDRA™ Technology, a Singapore based medical device innovator focused on the treatment of peripheral artery disease (PAD), for marketing and commercialization of its perfusion monitoring technology. Proximo Medical is a fractional commercial organization […]

Cardiovascular Systems, Inc. Announces Stephen Stenbeck Joins Board of Directors

Brent Blackey Retires after 12 Years of Service ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the addition of independent board member Stephen Stenbeck. He replaces independent director […]

Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

– NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company’s Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today reported financial results for the third […]

Canon Medical Supports Expert Forums on Advancements in Imaging Technology at RSNA 2019

Fourth Annual CME Symposia to Discuss Advances in MR & CT Imaging and Ultrasound Imaging for MSK and Sports Medicine CHICAGO–(BUSINESS WIRE)–In an effort to help clinicians stay current with the latest advancements in medical imaging, Canon Medical Systems, USA, through an unrestricted educational grant, invites you to expert-led forums […]

Neovasc Reducer™ Therapy for Refractory Angina Exceeds 200th Patient Milestone in Germany

VANCOUVER and MAINZ, Germany, Nov. 12, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a […]

New Study Shows Promise in Treating More Patients with World’s Smallest Pacemaker

Data Published in JACC: Clinical Electrophysiology and to be Presented at American Heart Association Scientific Sessions Demonstrates the Potential of Investigational Algorithms in Medtronic Micra Pacemaker to Improve Synchrony and Cardiac Function in AV Block Patients DUBLIN, Nov. 11, 2019 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced results from the MARVEL […]

MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

Achieved Primary Study Objective of Safety and Tolerability in Patients with Non-obstructive HCM Significant Reductions in Biomarkers of Cardiac Stress Observed in Patients on Treatment vs. Placebo Data Support Advancement of Mavacamten in Non-obstructive HCM; Regulatory Update Anticipated in the First Half of 2020 Phase 2 Study of Mavacamten Targeting […]

REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular Risk Reductions Across a Variety of Study Endpoints, Including Cardiovascular Death and All-Cause Mortality

Prespecified Analysis of 3,146 Patients in the USA Enrolled in REDUCE-IT Showed 31% Relative Risk Reductions for First Occurrence of Both 5-Point MACE and 3-Point MACE Significant Reductions Shown in All Predefined Composite and Individual Cardiovascular Endpoints, Including Cardiovascular Death and All-Cause Mortality Tolerability and Safety Findings Consistent with Full […]